Search results
Showing 7996 to 8010 of 8993 results
Discontinued Reference number: GID-TA10843
This guidance has been withdrawn because Cartiva Synthetic Cartilage Implant (SCI) has been recalled, and the evidence for this guidance was based solely on Cartiva SCI. More information is available in the field safety notice issued by Stryker. Surgeons are advised not to implant this device, to return any unused devices to Stryker and to consider reviewing any patients who have had Cartiva SCI. NICE will consider issuing new guidance on synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus) if evidence using an appropriately CE-marked device becomes available.
Leadless cardiac pacemaker implantation for bradyarrhythmias (HTG484)
This guidance has been updated and replaced by NICE HealthTech guidance 770.
Duvelisib for treating relapsed or refractory peripheral T-cell lymphoma [ID5076]
Discontinued Reference number: GID-TA10961
Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]
In development Reference number: GID-TA11481 Expected publication date: TBC
In development Reference number: GID-TA11908 Expected publication date: TBC
Discontinued Reference number: GID-TA10185
Digital technologies to support smoking cessation in secondary care patients: early value assessment
In development Reference number: GID-HTE10061 Expected publication date: TBC
Vosoritide for treating achondroplasia in people 4 months and over [ID6488]
In development Reference number: GID-TA11528 Expected publication date: TBC
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Interventional procedures, IPG463 - Issued: August 2013 --> This guidance has been updated and replaced by NICE HealthTech guidance 599.
We have moved interventional procedures guidance 789 to become HealthTech guidance 723. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST12)
This guidance has been updated and replaced by NICE's highly specialised technologies guidance 34.
This indicator has been updated and replaced by NICE indicator 324.